Arcus Biosciences, Inc. (NYSE: RCUS) announced on February 18, 2025, that it has entered into an underwriting agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC for the offering, issuance ...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...

Arcus Biosciences (RCUS) stock falls as Gilead (GILD) decides not to buy rights to its anticancer drug casdatifan. Read more here.

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory ...

Arcus Biosciences shares were down 14%, to $11.33, after the company priced a $150 million stock offering. Shares of the biopharmaceutical company hit their 52-week low of $10.65 earlier in the ...

Arcus Biosciences, Inc. has regained ownership of casdatifan, a potential treatment for clear cell renal cell carcinoma (ccRCC), after Gilead’s time-limited exclusive option rights to casdatifan ...

US pharma giant Merck & Co today announced that the European Commission (EC) has conditionally approved two indications for Welireg (belzutifan), its oral hypoxia-inducible factor-2 alpha (HIF-2α) ...

California-based Arcus Biosciences, a biopharma developing differentiated molecules and combination therapies for people with ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.